STOCK TITAN
  1. Home
  2. Sec-filings
  3. FMS
  4. [6-K] Fresenius Medical Care AG Current Report (Foreign Issuer)

Fresenius Medical Care (NYSE: FMS) lifts Q2 2026 profit 23% above views

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Fresenius Medical Care AG reported unaudited second-quarter 2026 results that exceeded capital market expectations on both profit and sales. Operating income excluding special items was EUR 569 million, up 23% at constant currency from the prior year and above the EUR 515 million consensus.

Group revenue rose 4% at constant currency to EUR 4,861 million, slightly above the EUR 4,792 million consensus. The company confirmed its unchanged financial outlook for the full year 2026, based on constant currency and figures excluding special items.

Positive

  • Operating income excluding special items of EUR 569 million grew 23% at constant currency year-on-year and came in above capital market consensus of EUR 515 million.
  • Group revenue of EUR 4,861 million increased 4% at constant currency compared to the prior year and was slightly above the EUR 4,792 million market consensus, while the company confirmed its full-year 2026 outlook.

Negative

  • None.
Operating income excluding special items EUR 569 million Unaudited Q2 2026 operating income excluding special items, up 23% at constant currency year-on-year
Operating income consensus EUR 515 million Capital market consensus for Q2 2026 operating income excluding special items
Operating income growth 23% Year-on-year increase at constant currency in Q2 2026 operating income excluding special items
Group revenue EUR 4,861 million Q2 2026 group revenue, up 4% at constant currency versus prior year
Revenue consensus EUR 4,792 million Capital market consensus for Q2 2026 group revenue
Revenue growth 4% Year-on-year group revenue growth at constant currency in Q2 2026
operating income excluding special items financial
"Operating income excluding special items amounts to EUR 569 million"
constant currency financial
"up 23% (at constant currency) compared to prior year"
Constant currency is a way of measuring financial results that removes the effects of changes in currency exchange rates. It allows for a clearer comparison of a company's performance over time by showing what the numbers would look like if exchange rates had stayed the same. This helps investors understand whether growth comes from actual business improvements or just currency fluctuations.
capital market expectations financial
"slightly above capital market expectations (consensus) of EUR 4,792 million"
financial outlook financial
"The company confirms its unchanged financial outlook for the full year 2026"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What operating income did Fresenius Medical Care (FMS) report for Q2 2026?
Fresenius Medical Care reported unaudited Q2 2026 operating income excluding special items of EUR 569 million, up 23% at constant currency versus the prior year and above capital market consensus expectations of EUR 515 million.

How did Fresenius Medical Care (FMS) Q2 2026 revenue compare with expectations?
Group revenue in Q2 2026 was EUR 4,861 million, representing 4% growth at constant currency compared to the prior year and coming in slightly above capital market expectations, which stood at EUR 4,792 million.

Did Fresenius Medical Care (FMS) confirm its financial outlook for 2026?
Yes. Fresenius Medical Care confirmed its unchanged financial outlook for the full year 2026. The guidance is based on revenue and operating income at constant currency and excluding special items, aligning with the company’s defined financial targets.

What does "excluding special items" mean in Fresenius Medical Care (FMS) results?
“Excluding special items” means the figures remove effects that are unusual in nature or not foreseeable in size or impact when the outlook was set. This approach aims to ensure comparability with Fresenius Medical Care’s financial targets, which are defined on the same basis.

On what assumptions is Fresenius Medical Care (FMS) 2026 outlook based?
The 2026 outlook assumes current laws, policies, regulations and tariffs remain in place. It is expressed on a constant currency basis and excludes special items, so that reported revenue and operating income align with the company’s target framework.

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

 

For the month of August 2026

 

Commission file number: 001-32749

 

FRESENIUS MEDICAL CARE AG

(Translation of registrant's name into English)

 

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                Form 40-F ¨

 

 

 

 

 

EXHIBITS

 

The following exhibits are being furnished with this Report:

 

Exhibit 99.1Convenience translation of an Ad-hoc release issued by the Company on August 3, 2026.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

DATE: August 3, 2026

 

  Fresenius Medical Care AG
   
  By: /s/ Helen Giza
  Name: Helen Giza
  Title: Chief Executive Officer and Chair of the Management Board

 

  By: /s/ Martin Fischer
  Name: Martin Fischer
  Title: Chief Financial Officer and member of the Management Board

 

 

 

Exhibit 99.1

 

 

HEADLINE: Fresenius Medical Care reports operating income excluding special items to be above market expectations in the second quarter of 2026 and confirms its outlook for the financial year 2026

 

Fresenius Medical Care AG reports financial results for the second quarter of 2026 (unaudited) above market expectations.

 

Operating income excluding special items amounts to EUR 569 million, up 23% (at constant currency) compared to prior year, driven by stronger operating income growth in the Care Delivery segment than expected by the capital market. This value is above market expectation (consensus) of EUR 515 million.

 

Group revenue increased by 4% (at constant currency) to EUR 4,861 million compared to prior year. This value is slightly above capital market expectations (consensus) of EUR 4,792 million.

 

The company confirms its unchanged financial outlook for the full year 2026.

 

Note: Revenue and operating income, as referred to in the outlook, are both on a constant currency basis and excluding special items. Special items will capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of providing the outlook. These items are excluded to ensure comparability of the figures presented with the company’s financial targets which have been defined excluding special items. Growth is measured year-on-year. The outlook assumes current laws/policies/regulations and tariffs. Details are disclosed in the reconciliation tables in the press release and financial tables document of the financial reporting for the 2nd quarter of 2026, to be published immediately after publication of this ad hoc announcement on the company’s website.

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases